IGHMBP2

Across TCGA pan-cancer cohorts, IGHMBP2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IGHMBP2 data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher IGHMBP2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated IGHMBP2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and CCRCC show a favorable association.

PDAC, UCEC, and CCRCC are the cancer types where IGHMBP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.311	0.759	<.001	74	view →
UCEC	DFS	Median	III,IV	1.000	0.386	.002	44	view →
CCRCC	OS	Median	All	0.908	0.761	.019	13	view →
HNSC	DFS	Quartile	All	1.000	0.877	.007	12	view →
LUAD	DFS	Median	III,IV	0.972	0.508	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IGHMBP2–PDAC (OS)

Open the PDAC breakdown →